Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website


Volume 8, Number 1, January 2016, pages 10-14

Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering


Figure 1.
Figure 1. Possible anti-atherosclerotic effects beyond glucose lowering of sodium glucose cotransporter 2 inhibitors. HDL-C: high-density lipoprotein-cholesterol; SGLT-2: sodium glucose cotransporter 2; TG: triglyceride.


Table 1. The Reported Sodium Glucose Cotransporter 2 Inhibitors
The search strategies by PubmedPublished articles (n)
Sodium glucose cotransporter 2 inhibitor OR sodium glucose cotransporter 2 inhibitors OR SGLT2 inhibitor OR SGLT2 inhibitors OR SGLT-2 inhibitor OR SGLT-2 inhibitors770
Each sodium glucose cotransporter 2 inhibitors


Table 2. The Search Strategy to Find the Anti-Atherosclerotic Effects of Dapagliflozin
The search strategy by using PubmedPublished articles (n)
Dapagliflozin and body weight106
Dapagliflozin and blood pressure78
Dapagliflozin and body fat OR dapagliflozin and visceral fat OR dapagliflozin and waist circumference OR dapagliflozin and abdominal circumference4
Dapagliflozin and insulin resistance OR dapagliflozin and insulin sensitivity38
Dapagliflozin and low density lipoprotein OR dapagliflozin and LDL5
Dapagliflozin and high density lipoprotein OR dapagliflozin and HDL6
Dapagliflozin and triglyceride4
Dapagliflozin and adiponectin0
Dapagliflozin and CRP OR dapagliflozin and C-reactive protein1
Dapagliflozin and necrosis factor alpha OR dapagliflozin and TNF-α0
Dapagliflozin and interleukin-6 OR dapagliflozin and IL-60
Dapagliflozin and cytokine OR dapagliflozin and cytokines2